Hualan Biological EngineeringInc (002007.SZ) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · China · ISIN CNE000001JN8
Hualan Biological EngineeringInc financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 4.38 bn CNY | 4.58 bn CNY |
| Gross profit | 2.61 bn CNY | 2.51 bn CNY |
| Operating income | 1.38 bn CNY | 1.13 bn CNY |
| EBIT | 1.18 bn CNY | 1.13 bn CNY |
| Net income | 1.09 bn CNY | 940.40 m CNY |
| Diluted EPS – continuing operations | 0.59 CNY | 0.51 CNY |
Full history since 2001, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Hualan Biological EngineeringInc
Hualan Biological Engineering Inc., together with its subsidiaries, engages in the research, development, production, and sale of biological products in China and internationally. The company offers blood products, including human serum albumin, human prothrombin complex concentrate, human coagulation factor VIII, human fibrinogen, and freeze-dried human fibrin glue for surgical use, as well as intravenous, human, rabies, hepatitis B, and tetanus immunoglobulin for various therapeutic applications. It also provides vaccine products, such as influenza virus split, H1N1 influenza A virus split, quadrivalent influenza virus split, group A and C meningococcal polysaccharide, group ACYW135 meningococcal polysaccharide, recombinant hepatitis B vaccine, freeze-dried human rabies, and adsorbed tetanus vaccines. In addition, the company develops monoclonal antibody drugs and biosimilars comprising rituximab injection which is in Phase III clinical trials for the treatment of CD20-positive diffuse large B-cell/follicular non-Hodgkin lymphoma and chronic lymphocytic leukemia; adalimumab injection which is in Phase III clinical trials for the treatment of various autoimmune diseases; denosumab injection which is in Phase III clinical trials for the treatment of patients with bone metastases; injectable trastuzumab which is in Phase III clinical trials for the treatment of HER2-positive metastatic/early-stage breast cancer and metastatic gastric cancer; and recombinant Exendin-4-FC fusion protein injection which is in Phase I/II clinical trials for the treatment of type 2 diabetes. Further, it is involved in the research and development of poultry farming; plasma collection; engineering technology research and experimental development; and inspection and testing services. The company was founded in 1992 and is headquartered in Xinxiang, China.
More stocks
- Mueller Water Products, Inc. (MWA)
- Societatea Nationala de Transport Gaze Naturale Transgaz SA (TGN.RO)
- ZIM Integrated Shipping Services Ltd (ZIM)
- Interparfums SA (ITP.PA)
- Qingdao Gon Technology Co Ltd (002768.SZ)
- Ventia Services Group Ltd (VNT.AX)
- Legend Biotech Corp (LEGN)
- Huber+Suhner AG (HUBN.SW)
- Iren SpA (IRE.MI)
- NCR Atleos Corp (NATL)
- AbCellera Biologics Inc. (ABCL)
- QinetiQ Group PLC (QQ.L)
Not investment advice. All data without warranty, price as of 23.10.2026. Details in the risk notice.